Art. -Nr.: HY-138939

5-LOX-IN-2

Kundenbewertung

Based on 1 Customer Validation

5-LOX-IN-2, an inhibitor of 5-lipoxygenase (5-LOX) with an IC₅₀ of 0.33 μM, inhibits 5-LOX in a dose-dependent manner . 5-LOX-IN-2, reduces the cell viability of renal cancer cells and induces apoptosis, can be used for cancer research.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 98.12%
CAS. Nr.: 179691-97-5
Formel: C₁₇H₁₆O₄
Molecular Weight:284.31

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

5-LOX-IN-2 Chemical Structure

CAS. Nr.: 179691-97-5

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
Chemical Information
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target^[1]

5-LOX

0.33 μM (IC₅₀)

Alle Lipoxygenase Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
786-0	IC₅₀	>100 μM Compound: 10b	Cytotoxicity against VHL-positive human 786-0 cells assessed as reduction in cell viability incubated for 4 days by XTT assay Cytotoxicity against VHL-positive human 786-0 cells assessed as reduction in cell viability incubated for 4 days by XTT assay	[PMID: 31260889]
786-0	IC₅₀	34.8 μM Compound: 10b	Cytotoxicity against VHL-deficient human 786-0 cells assessed as reduction in cell viability incubated for 4 days by XTT assay Cytotoxicity against VHL-deficient human 786-0 cells assessed as reduction in cell viability incubated for 4 days by XTT assay	[PMID: 31260889]
RCC4	IC₅₀	8 μM Compound: 10b	Cytotoxicity against VHL-deficient human RCC4 cells assessed as reduction in cell viability incubated for 4 days by XTT assay Cytotoxicity against VHL-deficient human RCC4 cells assessed as reduction in cell viability incubated for 4 days by XTT assay	[PMID: 31260889]
RCC4/VHL	IC₅₀	99.6 μM Compound: 10b	Cytotoxicity against VHL-positive human RCC4/VHL cells assessed as reduction in cell viability incubated for 4 days by XTT assay Cytotoxicity against VHL-positive human RCC4/VHL cells assessed as reduction in cell viability incubated for 4 days by XTT assay	[PMID: 31260889]

In Vitro

5-LOX-IN-2 (Compound 10b) (0-100 μM; 4 days) reduces the cell viability of renal cancer cells^[1].
5-LOX-IN-2 (Compound 10b) (0-10 μM; 24 hours) increases in LC3B and p62 expression, blocks of the autophagic flux in RCC4 cells, and induces apoptosis by activation of the caspase-3 pathway leading to cell death^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[1]

Cell Line:

RCC4, RCC10, 786.0 cells
Concentration:

0-100 μM
Incubation Time:

4 days
Result:

Reduced the cell viability of renal cancer cells and was more selective toward RCC4 and 786.0 cells which are deficient for the Von Hippel-Lindau (VHL) tumor suppressor gene.

Western Blot Analysis^[1]

Cell Line:

RCC4, RCC10, 786.0 cells
Concentration:

0-10 μM
Incubation Time:

24 hours
Result:

Increased in LC3B and p62 expression, blocked of the autophagic flux in RCC4 cells.
Stimulated in a dose ependent manner the cleavage of pro-caspase-3 only in the RCC4 cells which lack the VHL tumor suppressor.

Chemical Information

CAS. Nr. 179691-97-5
Appearance Solid
Molecular Weight 284.31
Formel C₁₇H₁₆O₄
Color Off-white to light yellow
SMILES

O=C(OCCC1=CC=CC=C1)/C=C/C2=CC(O)=CC=C2O
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 100 mg/mL (351.73 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.5173 mL

17.5864 mL

35.1729 mL

5 mM

0.7035 mL

3.5173 mL

7.0346 mL

10 mM

0.3517 mL

1.7586 mL

3.5173 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (8.79 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (271 KB)
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Selka A, et.al. Discovery of a novel 2,5-dihydroxycinnamic acid-based 5-lipoxygenase inhibitor that induces apoptosis and may impair autophagic flux in RCC4 renal cancer cells. Eur J Med Chem. 2019 Oct 1;179:347-357. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	3.5173 mL	17.5864 mL	35.1729 mL	87.9322 mL
	5 mM	0.7035 mL	3.5173 mL	7.0346 mL	17.5864 mL
	10 mM	0.3517 mL	1.7586 mL	3.5173 mL	8.7932 mL
	15 mM	0.2345 mL	1.1724 mL	2.3449 mL	5.8621 mL
	20 mM	0.1759 mL	0.8793 mL	1.7586 mL	4.3966 mL
	25 mM	0.1407 mL	0.7035 mL	1.4069 mL	3.5173 mL
	30 mM	0.1172 mL	0.5862 mL	1.1724 mL	2.9311 mL
	40 mM	0.0879 mL	0.4397 mL	0.8793 mL	2.1983 mL
	50 mM	0.0703 mL	0.3517 mL	0.7035 mL	1.7586 mL
	60 mM	0.0586 mL	0.2931 mL	0.5862 mL	1.4655 mL
	80 mM	0.0440 mL	0.2198 mL	0.4397 mL	1.0992 mL
	100 mM	0.0352 mL	0.1759 mL	0.3517 mL	0.8793 mL

Keywords

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

5-LOX-IN-2

Bioactive Compound Library Max

Bioactive Compound Library

Immunology/Inflammation Compound Library

Metabolism/Protease Compound Library

Anti-Cancer Compound Library

Ferroptosis Compound Library

Lipid Metabolism Compound Library

Anti-Prostate Cancer Compound Library

Metabolic Enzyme Compound Library

Highly Selective Inhibitors Library

MCE Bioactive Compound Library

Anti-Fibrosis Compound Library

High-Throughput Bioactive Compound Library

Alle Lipoxygenase Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

5-LOX-IN-2

Bioactive Compound Library Max

Bioactive Compound Library

Immunology/Inflammation Compound Library

Metabolism/Protease Compound Library

Anti-Cancer Compound Library

Ferroptosis Compound Library

Lipid Metabolism Compound Library

Anti-Prostate Cancer Compound Library

Metabolic Enzyme Compound Library

Highly Selective Inhibitors Library

MCE Bioactive Compound Library

Anti-Fibrosis Compound Library

High-Throughput Bioactive Compound Library

Alle Lipoxygenase Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

5-LOX-IN-2 Related Classifications

HY-138939 Related Classifications